Department of Infectious Disease Epidemiology, MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK
Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
BMJ Glob Health. 2021 Jul;6(Suppl 4). doi: 10.1136/bmjgh-2020-004543.
OBJECTIVES: Ending HIV by 2030 is a global priority. Achieving this requires alternative HIV testing strategies, such as HIV self-testing (HIVST) to reach all individuals with HIV testing services (HTS). We present the results of a trial evaluating the impact of community-based distribution of HIVST in community and facility settings on the uptake of HTS in rural and urban Zambia. DESIGN: Pair-matched cluster randomised trial. METHODS: In catchment areas of government health facilities, OraQuick HIVST kits were distributed by community-based distributors (CBDs) over 12 months in 2016-2017. Within matched pairs, clusters were randomised to receive the HIVST intervention or standard of care (SOC). Individuals aged ≥16 years were eligible for HIVST. Within communities, CBDs offered HIVST in high traffic areas, door to door and at healthcare facilities. The primary outcome was self-reported recent testing within the previous 12 months measured using a population-based survey. RESULTS: In six intervention clusters (population 148 541), 60 CBDs distributed 65 585 HIVST kits. A recent test was reported by 66% (1622/2465) in the intervention arm compared with 60% (1456/2429) in SOC arm (adjusted risk ratio 1.08, 95% CI 0.94 to 1.24; p=0.15). Uptake of the HIVST intervention was low: 24% of respondents in the intervention arm (585/2493) used an HIVST kit in the previous 12 months. No social harms were identified during implementation. CONCLUSION: Despite distributing a large number of HIVST kits, we found no evidence that this community-based HIVST distribution intervention increased HTS uptake. Other models of HIVST distribution, including secondary distribution and community-designed distribution models, provide alternative strategies to reach target populations. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT02793804).
目标:到 2030 年终结艾滋病是全球重点。要实现这一目标,需要采用其他艾滋病毒检测策略,例如艾滋病毒自我检测(HIVST),以让所有艾滋病毒检测服务(HTS)对象接受检测。我们展示了一项评估在赞比亚城乡社区和医疗机构环境中,以社区为基础分发 HIVST 对 HTS 接受率影响的试验结果。
设计:配对的集群随机试验。
方法:在政府卫生机构的服务区内,社区为基础的分发者(CBD)在 2016 年至 2017 年的 12 个月内分发 OraQuick HIVST 试剂盒。在配对的集群内,集群被随机分配接受 HIVST 干预或标准护理(SOC)。年龄≥16 岁的人均有资格接受 HIVST。在社区内,CBD 在交通繁忙地区、挨家挨户和医疗机构提供 HIVST。主要结果是在过去 12 个月内使用基于人群的调查报告的最近检测。
结果:在六个干预集群(人口 148541 人)中,有 60 名 CBD 分发了 65585 份 HIVST 试剂盒。干预组中有 66%(1622/2465)的人报告了最近一次检测,而 SOC 组中有 60%(1456/2429)的人报告了最近一次检测(调整后的风险比 1.08,95%CI 0.94 至 1.24;p=0.15)。HIVST 干预措施的接受率很低:在干预组中,24%(585/2493)的受访者在过去 12 个月内使用了 HIVST 试剂盒。在实施过程中未发现任何社会危害。
结论:尽管分发了大量的 HIVST 试剂盒,但我们没有发现这种基于社区的 HIVST 分发干预措施能增加 HTS 接受率的证据。其他 HIVST 分发模式,包括二级分发和社区设计的分发模式,为覆盖目标人群提供了替代策略。
试验注册:ClinicalTrials.gov 注册表(NCT02793804)。
Expert Rev Mol Diagn. 2023-3
J Acquir Immune Defic Syndr. 2018-3-1